BLENREP▼ (Belantamab mafodotin) logo

Product menu

NA NA
Picture showing increasing arrow on a green background

BLENREP + Vd

DREAMM-7 efficacy and safety profile
Picture showing increasing arrow on a pink background

BLENREP + Pd

DREAMM-8 efficacy and safety profile
Picture showing a lightbulb lit up on a green background

2L therapy options with different MoAs are needed to improve outcomes for LEN-refractory patients3

Patients need the most effective therapy available at each line of relapse, as active treatment rates decline with each successive line of therapy.4–6

Outcomes in 2L

Image showing a BLENREP (belantamab mafodotin) molecule

Help your eligible patients navigate first relapse by changing drug class with BLENREP (belantamab mafodotin)1

BLENREP is the first approved BCMA antibody-drug conjugate treatment for use in multiple myeloma at 2L.1,7–10 It is engineered to target multiple myeloma by enhancing anti-tumour immunity and delivering an intracellular cytotoxic payload.1

BCMA is a clinically relevant therapeutic target in multiple myeloma due to its selective expression on multiple myeloma cells, while being largely absent on normal tissues.11,12

About BLENREP MoA

Treatment guidance and patient support

Image showing an IV bag

BLENREP dosing and administration

BLENREP offers your eligible patients an infusion time of a minimum of 30 minutes and no SPC-specified post-infusion monitoring window or routine hospitalisation for administration, beyond your normal clinical practice.*1

Discover BLENREP
Image showing a shield with a cross

Managing side effects

BLENREP dosing can be delayed, reduced, or discontinued as part of a strategy to manage side effects.†1

Find out more about the SPC guidance on the eye- and non-eye-related side effects of BLENREP-based combinations in patients with multiple myeloma.‡1

Managing side effects
NA

Getting started with BLENREP

Discover practical guidance to support patients on BLENREP, including eye care advice, side effect monitoring, and how to collaborate with eye care professionals throughout your patients’ treatment journey.1

Support your patients

*Monitor patients for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion and provide supportive treatment. Once symptoms resolve, resume BLENREP at a lower infusion rate. For patients with Grade 3 infusion-related reactions, administer pre-medication for all subsequent infusions. Discontinue BLENREP for life-threatening infusion-related reactions and provide appropriate emergency care.1 †Discontinuation rate of any component of therapy in the DREAMM-7 study was 31%, and in the DREAMM-8 study it was 15%. ‡Eye-related side effects have been reported with the use of BLENREP. For more information, including dose adjustments and monitoring, please see the SPC, and continue to the side effects page.

More resources

Image showing a man dressed as a gardener

Resources

Access practical tools and information to help support your patients throughout their treatment journey.

Resources
Image showing a man dressed in a suit

News and updates

Read the latest developments, clinical insights, and updates relating to BLENREP.

News
Image showing a woman wearing a sports outfit

Expert insights

Hear from healthcare professionals sharing real-world experiences and best practices in BLENREP treatment.

Expert insights

Patients who are refractory to lenalidomide may need 2L therapy options with different MoAs to improve outcomes.3

Discover the unmet need in 2L multiple myeloma

Abbreviations

2L, second line; BCMA, B-cell maturation antigen; LEN, lenalidomide; MoA, mechanism of action; NICE, National Institute for Health and Care Excellence; Pd, pomalidomide and dexamethasone; SPC, Summary of Product Characteristics; Vd, bortezomib and dexamethasone.

References

  1. BLENREP Summary of Product Characteristics. GlaxoSmithKline. 2025.
  2. NICE. ID6212. 2025, Available at https://www.nice.org.uk/guidance/indevelopment/gid-ta11203. Accessed October 2025.
  3. Moore S, et al. eJHaem. 2024;1–12.
  4. Bhatt P, et al. Curr Oncol. 2023;30(2):2322–2347.
  5. Kumar S, et al. Blood Cancer J. 2022;12(6):98. doi:10.1038/s41408-022-00695-5.
  6. Raab MS, et al. Br J Haematol. 2019;185:981–984.
  7. Darzalex. Summary of Product Characteristics. Janssen-Cilag Ltd.
  8. Kyprolis. Summary of Product Characteristics. Amgen Ltd.
  9. Nexpovio. Summary of Product Characteristics. Menarini Stemline UK Ltd.
  10. Revlimid. Summary of Product Characteristics. Bristol Myers Squibb Pharmaceuticals limited.
  11. Kleber M, et al. J Clin Med. 2021;10(18):4088.
  12. Shah N, et al. Leukemia. 2020;34:985–1005.

▼This product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (available on the Apple App Store or Google Play Store). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.

PM-GB-BLM-WCNT-250012 | October 2025 (V1.0)